Skip to main content
Premium Trial:

Request an Annual Quote

Tufts' Clinical and Translational Science Institute Lands $24M from NIH

NEW YORK (GenomeWeb News) – Tufts University Medical Center has received $24 million from the National Institutes of Health to fund its Clinical and Translational Science Institute (CTSI), which hosts core facilities for nucleic acid analysis, a biorepository, training and consultation programs, and other services, Tufts said on Wednesday.

Tufts said its CTSI collaborates with 39 partners, which includes 12 schools and research centers at the university, 10 affiliated hospitals, and five industry partners, among others.

Richard Karas, the chief scientific officer at Tufts Medical Center, said the CTSI, which first received funding in 2008, provides support for clinical trials, lab research, study design, funding for pilot studies, and career development programs.

The CTSI's core center, the Clinical and Translational Research Center, provides a range of services, including specimen processing, storage, and shipping, nucleic acid analysis, immunoassays, and access to bench and freezer space. The CTSI's specimen processing services include DNA and RNA isolation, and its nucleic acid analysis offerings include DNA and RNA analysis, real-time PCR assays, whole genome amplification, and library preparation for next-generation sequencing.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.